Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

CAARE Joins Inaugural 'World Day of Animal Free Research' on May 27; Notes U.S. Legislation to Remove FDA's Animal Testing Mandate


News provided by

CAARE

May 26, 2022, 16:00 ET

Share this article

Share toX

Share this article

Share toX


World Day for Animal Free Research was established to lend urgency and importance to the need and capability to replace animals in experimentation. On this inaugural day, Citizens for Alternatives to Animal Research and Experimentation is highlighting pending federal legislation with the potential to pass this year that will remove the animal testing mandate from the FDA.

NEW YORK, May 26, 2022  /PRNewswire-PRWeb/ -- Citizens for Alternatives to Animals in Research and Experimentation (CAARE) – a non-governmental nonprofit that is promoting federal legislation to phase out the use of animals in testing – has announced its participation in the inaugural World Day of Animal Free Research on May 27, 2022, introduced in the UK by the organization, Animal Free Research.

CAARE was established in 2014 with the goal of ending the use of animals in experiments by demonstrating how they impede medical progress, and how they can be replaced with scientifically and morally superior methods.

“Cutting-edge technology has forged new frontiers in biology and medicine that have produced human-relevant models that can replace animals. It is time for federal funding and regulation to keep pace with scientific innovation by investing in non-animal research.”

Post this

"Cutting-edge technology has forged new frontiers in biology and medicine that have produced human-relevant models that can replace animals. These include organoid cell cultures, organs-on-chips, genomics, sophisticated computer models, and much more," said Barbara Stagno, CAARE's president.

An estimated 90 to 95 percent of drugs and vaccines found safe in animal tests fail during human clinical trials. The cost for developing a single new drug may be from $1 - $6 billion and takes an average of 10 to 15 years from lab to market. See here, here, here and here . The problem can be addressed by using ethical, human-relevant test methods to develop safer and more effective treatments.

As an example, researchers recently assessed the performance of Liver-Chips – miniaturized organs-on-a chip developed by biotech company Emulate, Inc. – to evaluate the toxicity of 22 known drugs.

The study demonstrated that the Liver-Chip was able to correctly identify 87 percent of the tested drugs that had caused drug-induced liver injury in patients after passing through animal testing.

Notably, the liver damage experience by these patients resulted in 208 fatalities and 10 liver transplants. Had these drugs been tested using the Liver-Chip, it appears likely that many of these fatalities and severe liver injuries would have been avoided.

"It is time for federal funding and regulation to keep pace with scientific innovation by investing in non-animal research," said CAARE, which has worked to develop and introduce a landmark piece of federal legislation, The Humane Research and Testing Act of 2021 (H.R. 1744) to create a federal institute to fund and promote research without animals.

H.R. 1744 will establish the National Center for Alternatives to Animals in Research under the National Institutes of Health to develop, fund and incentivize scientists to use non-animal methods of research, supporting scientists to carry out the most modern and innovative human-relevant research.

Additionally, CAARE is working with its affiliate, the Center for a Humane Economy, to advance legislation that would end the requirement by the U.S. Food and Drug Administration (FDA) that all new drug candidates be tested on animals.

The FDA Modernization Act of 2021, (H.R. 2565 and S. 2952), would eliminate the requirement that all new drugs go through extensive rounds of animal testing. It will, for the first time, allow drug developers to use methods other than animal testing to establish the drug's safety and effectiveness.

On May 18, the FDA Modernization Act, now incorporated into a broader legislative packet (H.R. 7667) passed the powerful House Energy and Commerce Committee unanimously.

It will come before the full house for a vote in mid-June. The package is part of the required five-year renewal for FDA's funding structure and as such is considered a "must pass" before the September 30 expiration.

"This is truly a breakthrough. The bill stands a good chance of enactment in the next few months, and with that, the end of an outdated paradigm that mandates drug testing on animals," said Stagno.

"World Day for Animal Free Research recognizes that it's time we put more resources into modernizing medicine by shifting away from animals. The burgeoning evidence shows that this will improve outcomes for humans and animals."

"That the FDA Modernization Act is on a fast track to enactment, with robust bipartisan support in both chambers, shows that our lawmakers have come to understand the flaws of animal research. Though the final result has yet to be determined, we are excited that the current trajectory portends a groundbreaking outcome."

The FDA Modernization Act was initiated by the Center for a Humane Economy and powered by a coalition of groups that includes CAARE, Animal Wellness Action, the Animal Wellness Foundation, the Michelson Center for Public Policy, People for the Ethical Treatment of Animals, and backed by an alliance of over 120 entities comprising animal welfare, patient advocacy and biotech companies.

Citizens for Alternatives to Animal Research and Experimentation (CAARE), is a 501(c)(3) non-profit organization, established to highlight and promote research without animals.

CAARE is a proud affiliate of the Center for a Humane Economy, dedicated to forging a humane economic order.

Media Contact

Barbara Stagno, CAARE, 1 9148390857, [email protected]

SOURCE CAARE

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.